Overview
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
Status:
Completed
Completed
Trial end date:
2007-11-01
2007-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathyPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:- Diagnosis of diabetic peripheral neuropathy
- Moderate to severe neuropathic pain
Exclusion Criteria:
- Any other uncontrolled disease
- Pregnant or nursing females